1913O Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET+ MTC)

Mimi I. Hu, Vivek Subbiah, Lori J. Wirth, M Schuler, Aaron S. Mansfield, Marcia S. Brose, Giuseppe Curigliano, Sophie Leboulleux, Viola W. Zhu, Bhumsuk Keam, Ignacio Matos, C-C. Lin, D.R. Adkins, Christina S. Baik, G. Lopes, Yann Godbert, Debashis Sarker, H. Zhang, Christopher D. Turner, Matthew Taylor